Glembatumumab Vedotin

1 1

Selleck Chemicals

D4054-1MG

€953,00 EUR
€953,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

Glembatumumab Vedotin is an antibody-drug conjugate (ADC) composed of a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to monomethyl auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.

Product overview

Glembatumumab vedotin is relevant to research on Breast cancer (TNBC) and advanced or metastatic melanoma. The product background identifies the antibody component, target antigen and payload or linker architecture where these details are supplied. This ADC context supports comparison of antigen recognition, payload conjugation and cellular uptake behavior in controlled assay systems, especially when researchers need to distinguish conjugated biologics from unconjugated antibodies or standalone small molecules.

Laboratory context

The listed workflow context supports binding and uptake-oriented laboratory studies where a defined antibody component, cellular target and conjugated payload are relevant to assay planning, including cell-surface binding, cell-uptake and protein-binding experiments, within oncology research.

Research Area:
Oncology
Application:
Cell Surface Binding • Cell Uptake Studies • Protein Binding
Formulation:
1xPBS
CAS No.:
1182215-65-1
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.